Search Bar & Filters
Found 14 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the safety and effectiveness of a drug called tacabrutideg for people with B-cell malignancies, a type of cancer that affects white blood cells. These cancers include various forms such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and others. The study aims to find the best dose of tacabrutideg and evaluate how well it works in shrinking or eliminating these cancers. The study has two parts first, a dose escalation phase where different doses of tacabrutideg are tested to find a recommended dose that is safe and tolerable. Then, an expansion phase enrolls more participants to further assess the safety and effectiveness of the selected dose or doses. Tacabrutideg is given orally. The study includes multiple groups of participants with different types of B-cell malignancies, including some specific cohorts like Japanese participants and those who have not previously received certain kinase inhibitors. Participants will visit clinics regularly over about three years for treatment, health checks, blood tests, tumor imaging, and other assessments. Researchers will monitor side effects, measure cancer response, and collect blood samples to study how the drug behaves in the body. The main outcomes include safety, identifying the best dose, and overall cancer response rates. The study is open label, so both participants and doctors know the treatment given.
Actively Recruiting
Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of different doses of Pirtobrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Part 1 of the study focuses on participants who have received one to three prior treatments, including a covalent Bruton tyrosine kinase BTK inhibitor, while Part 2 studies treatment-nave participants with a specific genetic deletion 17p deletion. This trial is a Phase 2, open-label, randomized study sponsored by Loxo Oncology, Inc. Participants receive Pirtobrutinib orally in varying doses. In Part 1, three different doses are tested in participants with relapsed or refractory CLLSLL who have prior BTK inhibitor treatment. Part 2 evaluates Pirtobrutinib monotherapy at a standard dose in treatment-nave participants with 17p deletions. The study uses a parallel design with random assignment to treatment groups. Participants are involved for approximately three years in Part 1 and up to two years in Part 2. Researchers monitor overall response rate as the primary outcome, along with duration of response over this time. Participants must be able to swallow oral medication and have their health status regularly assessed, including physical performance scores. Safety and treatment effects are followed throughout the study period.
Actively Recruiting
Researchers are studying chronic primary immune thrombocytopenia ITP, a condition where the immune system mistakenly destroys platelets, leading to easier bruising and bleeding due to low platelet counts. The trial aims to evaluate whether mezagitamab, given as a subcutaneous injection, can maintain stable platelet levels in adults with ITP compared to a placebo. This Phase 3 study is randomized, double-blind, and placebo-controlled to thoroughly assess mezagitamabs effects. Participants will receive either mezagitamab or a matching placebo injection once weekly. The dosing schedule includes 8 weeks of weekly injections, followed by an 8-week break, and then another 8 weeks of weekly injections, totaling up to 6 months of treatment. Those who complete this study or do not respond by week 16 may have the option to join a continuation study to receive open-label mezagitamab if eligible. During the study, participants will visit the clinic multiple times for assessments. Researchers will monitor platelet counts regularly and evaluate responses using measures such as the percentage of participants with durable platelet response up to week 24. Additional assessments include symptom questionnaires, fatigue scores, bleeding events, and monitoring of mezagitamab levels and antibodies. The study also observes safety and treatment effects through week 24 and beyond as needed.
Actively Recruiting
Researchers are studying the safety and effectiveness of pirtobrutinib LOXO-305 compared to ibrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study includes participants who may or may not have received prior treatment for their cancer and focuses on those with specific genetic markers, like 17p deletions, in one part of the trial. This is a phase 3, open-label study sponsored by Loxo Oncology, Inc. Participants receive either pirtobrutinib or ibrutinib as oral treatments. The study has two parts Part 1 compares pirtobrutinib and ibrutinib in a broad group of participants and may last up to six years, while Part 2 evaluates pirtobrutinib alone in treatment-nafve participants with 17p deletions for up to two years. Treatments are taken by mouth, and participants are randomly assigned to treatment groups. During the study, participants will undergo regular assessments to monitor their response to treatment, including checking for complete or partial remission. Researchers will evaluate progression-free survival, overall survival, duration of response, and tolerability over several years. Safety and effectiveness are closely tracked with scheduled visits and tests until data cutoff or disease progression. Participation can last up to six years depending on the study part.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tacabrutideg compared with investigators choice treatments in people with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with both Bruton Tyrosine Kinase inhibitors BTKi and B-cell LeukemiaLymphoma 2 protein inhibitors BCL2i. This study aims to compare how long participants live without their disease worsening under these treatments. The study is a Phase 3, randomized trial sponsored by BeOne Medicines. Participants will be randomly assigned to receive either tacabrutideg taken orally once daily until treatment discontinuation criteria are met, or investigators choice of treatment. The investigators choice includes combinations such as idelalisib plus rituximab for CLL only, bendamustine plus rituximab, or venetoclax plus rituximab retreatment. Some of these drugs are administered orally while others are given intravenously. During the study, participants will be closely monitored for progression-free survival over approximately 36 months, along with overall survival and response rates. Researchers will assess quality of life using specific questionnaires for up to 24 months, and track treatment-emergent adverse events. The study involves regular assessments and evaluations to understand treatment effects and safety over the course of participation, which may last several years until study completion in 2030.
Actively Recruiting
Multiple myeloma is a type of blood cancer that affects plasma cells typically found in the bones and bone marrow. This cancer can cause bone pain, fractures, infections, weak bones, and kidney failure. The study is designed to evaluate the safety, effectiveness, and how the body processes two investigational drugs, Etentamig and ABBV-2001, in adults with multiple myeloma, including those newly diagnosed or with relapsed or refractory disease. The study includes eight substudies with dose escalation and expansion phases. Participants in substudies 1-4 will receive increasing doses of Etentamig alone or combined with other drugs like daratumumab, lenalidomide, carfilzomib, and dexamethasone, delivered intravenously or by subcutaneous injection. Substudies 5-8 involve up to two doses of ABBV-2001 combined with oral agents such as iberdomide, mezigdomide, pomalidomide, or lenalidomide. Treatments are given according to dose levels determined during escalation phases, and the total study duration is about 130 months. Throughout the study, participants will attend regular hospital or clinic visits for medical assessments, blood tests, and side effect monitoring. Researchers will use questionnaires and other evaluations to track treatment effects and adverse events. The primary outcomes include monitoring adverse events and dose-limiting toxicities, with secondary measures including response rates, progression-free survival, duration of response, time to progression, and minimal residual disease negativity over the course of the study.
Actively Recruiting
Researchers are comparing the effectiveness and safety of sonrotoclax combined with either obinutuzumab or rituximab against venetoclax combined with rituximab in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This phase 3 study aims to assess progression-free survival and other important outcomes among these treatment combinations to find better options for patients. Participants will be randomly assigned to one of four treatment groups sonrotoclax plus obinutuzumab, sonrotoclax plus rituximab, sonrotoclax plus obinutuzumab guided by minimal residual disease evaluation, or venetoclax plus rituximab. Sonrotoclax and venetoclax are given orally, while obinutuzumab and rituximab are given intravenously. The study includes detailed treatment schedules and monitoring of minimal residual disease in one group. During the study, participants will have regular evaluations including assessments by blinded independent review committees of progression-free survival, response rates, and overall survival. Quality of life and symptom burden will also be measured using specific questionnaires. Safety will be monitored from the first dose through follow-up periods lasting up to several years. The total study duration extends to approximately six years, with ongoing assessments to understand treatment effects and safety.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of sonrotoclax combined with zanubrutinib compared to zanubrutinib with placebo in adults who have relapsed or refractory mantle cell lymphoma MCL, a rare and aggressive blood cancer. The study focuses on whether the combination of sonrotoclax and zanubrutinib can better control the disease and improve patient outcomes. Participants will be randomly assigned to one of two groups one receiving sonrotoclax plus zanubrutinib, and the other receiving zanubrutinib plus a placebo. All treatments are taken orally. The placebo is a pill without active medicine. The study design is double-blind, so neither participants nor doctors know which treatment is given during the trial unless medically necessary. The study will last up to approximately 7 years. During this time, participants will visit clinics regularly for treatment, health assessments, blood tests, and tumor imaging. Researchers will measure how long participants live without disease worsening, overall survival, response rates, quality of life, and safety through side effect monitoring. These evaluations will help understand the treatments impact on the disease and patient wellbeing.
Actively Recruiting
Researchers are studying adults aged 45 to 80 who have high levels of Lipoproteina, known as Lpa, a protein linked to higher risk of heart disease. The trial aims to compare the effects of lepodisiran, a drug given by injection, to a placebo on the amount and type of plaque in the hearts vessels using advanced imaging called Coronary Computed Tomography Angiography CCTA. This study is a Phase 3 randomized, double-blind trial focusing on treatment for cardiovascular disease or risk for a first cardiovascular event. Participants will receive either lepodisiran or a placebo by subcutaneous injection. The study will follow them for about 120 weeks, including assessments at baseline and at Week 104 to measure changes in noncalcified plaque volume in the coronary arteries. Secondary measures include changes in fat attenuation index, Lpa levels, participant feedback on the injection experience, and drug pharmacokinetics. During the study, participants will undergo imaging scans, blood tests, and questionnaires at scheduled times to track the effects of the drug compared to placebo. Researchers will monitor the plaque in coronary arteries and Lpa levels to understand how lepodisiran may impact cardiovascular health. Safety and participant experience with the treatment will also be assessed throughout the trial duration.
1-10 of 14
1